Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Invests In Xenon’s Novel Anemia Treatment Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

Two-year licensing, equity investment deal with the Canadian drug discovery firm will explore protein modulators to treat anemia of inflammation.

You may also be interested in...

Roche Invests In Halozyme Biologics Delivery Platform

Halozyme’s Enhanze technology could be used with virtually all biologics to improve drug delivery, the company says.

Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks

CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts